- Home
- AGEN vs KVHI Comparison
AGEN vs KVHI Comparison
Compare AGEN & KVHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- KVHI
- Stock Information
- Founded
- AGEN 1994
- KVHI 1978
- Country
- AGEN United States
- KVHI United States
- Employees
- AGEN N/A
- KVHI N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- KVHI Radio And Television Broadcasting And Communications Equipment
- Sector
- AGEN Health Care
- KVHI Technology
- Exchange
- AGEN Nasdaq
- KVHI Nasdaq
- Market Cap
- AGEN 96.2M
- KVHI 108.1M
- IPO Year
- AGEN 2000
- KVHI 1996
- Fundamental
- Price
- AGEN $2.83
- KVHI $5.40
- Analyst Decision
- AGEN Buy
- KVHI
- Analyst Count
- AGEN 3
- KVHI 0
- Target Price
- AGEN $10.50
- KVHI N/A
- AVG Volume (30 Days)
- AGEN 566.5K
- KVHI 58.0K
- Earning Date
- AGEN 11-12-2024
- KVHI 11-07-2024
- Dividend Yield
- AGEN N/A
- KVHI N/A
- EPS Growth
- AGEN N/A
- KVHI N/A
- EPS
- AGEN N/A
- KVHI N/A
- Revenue
- AGEN $160,427,000.00
- KVHI $118,366,000.00
- Revenue This Year
- AGEN N/A
- KVHI N/A
- Revenue Next Year
- AGEN $36.13
- KVHI N/A
- P/E Ratio
- AGEN N/A
- KVHI N/A
- Revenue Growth
- AGEN 59.00
- KVHI N/A
- 52 Week Low
- AGEN $2.50
- KVHI $4.17
- 52 Week High
- AGEN $19.69
- KVHI $6.00
- Technical
- Relative Strength Index (RSI)
- AGEN 39.40
- KVHI 47.42
- Support Level
- AGEN $2.65
- KVHI $5.57
- Resistance Level
- AGEN $3.85
- KVHI $6.00
- Average True Range (ATR)
- AGEN 0.29
- KVHI 0.23
- MACD
- AGEN -0.02
- KVHI -0.08
- Stochastic Oscillator
- AGEN 15.00
- KVHI 28.40
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About KVHI KVH Industries Inc.
KVH Industries Inc provide integrated, end-to-end services, software, and hardware that support its customers' need for access to the Internet, VoIP, operations content, and entertainment services. The company also provides commercially licensed entertainment, including news, sports, music, and movies, to commercial and leisure customers in the maritime, hotel, and retail markets. The Company operates in a number of geographic areas, including internationally. The Revenues are generated from international locations, mainly consisting of Singapore, Canada, European Union countries and other European countries, countries in Africa, Asia/Pacific and the Middle East, and India.